Breast Cancer/Birads 4a: Biopsy Thresholds - Understanding the Gray Area

Introduction: Breast screening entails examining the breasts for cancer before any signs or symptoms of the disease emerge. While screening cannot prevent breast cancer, it plays a crucial role in detecting it early, when treatment is more effective. However, it's important to acknowledge that screening results may not always be denitive. False negatives occur when screening fails to detect cancer that is present, while false positives happen when screening indicates abnormalities that are not cancerous. Despite these limitations, breast screening remains a valuable tool in the ght against breast cancer. It offers the opportunity for early detection, enabling prompt intervention and potentially improving treatment outcomes for individuals diagnosed with the disease. This article examines the nuanced considerations surroun Objectives: ding the management of BIRADS 4a ndings, addressing the pivotal question: Should patients with BIRADS 4a ndings undergo biopsy? This Materials and Methods: cross-sectional study conducted in a retrospective manner, by analyzing the medical reports of all consecutive female patients examined at radiology department at King Hussein Medical Center (KHMC) for breast mass. Descriptive statistics were used to analyze the data and correlate mammogram results and histopathological reports. The study nal population included 112 patients who Results: met the inclusion/exclusion criteria. The age of patients was between 30 and 77 years with a mean age of 49±11 years. Most common age group in BIRAD 4a was 40-49 years old, 37.5% (42/112). Breast masses were encountered bilaterally in 7.14% (8/112) of patients, while right breast masses were revealed in 57.14% (64/112), and in left breast results showed 35.71% (40/112). Smokers were 27.68% of the total population (31/112) (Table. 1). Histopathological reports showed that 54.46% of patients (61/112) had benign lesions in BIRAD 4a group and only 21.43% (38/115) had malignant lesions. Conclusion: The management of BIRADS 4a ndings represents a complex clinical challenge, requiring careful consideration of various factors. While the decision to biopsy entails inherent risks, it also offers the opportunity for timely diagnosis and intervention. Advancements in imaging technology and biopsy techniques continue to rene our ability to characterize and sample suspicious lesions. A patient-centered approach that prioritizes shared decision-making and individualized care remains paramount in navigating the management of BIRADS 4a ndings.